DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the Chemotherapy Induced Nausea and Vomiting pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chemotherapy Induced Nausea and Vomiting pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chemotherapy Induced Nausea and Vomiting Pipeline. Dive into DelveInsight’s comprehensive report today! @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook

Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report

• In May 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie announced a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.
• DelveInsight’s Chemotherapy Induced Nausea and Vomiting Pipeline report depicts a robust space with 8+ active players working to develop 5+ pipeline therapies for Chemotherapy Induced Nausea and Vomiting treatment.
• The leading Chemotherapy Induced Nausea and Vomiting Companies such as Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.
• Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Palonosetron Hydrochloride Buccal Film 0.25 Mg, Akynzeo, Fosaprepitant Dimeglumine and others.

Stay ahead with the most recent pipeline outlook for Chemotherapy Induced Nausea and Vomiting. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chemotherapy Induced Nausea and Vomiting Treatment Drugs

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile

• Fosnetupitant: Helsinn Healthcare SA

Fosnetupitant is an NK1 receptor antagonist antiemetic drug developed for the prevention of chemotherapy-induced nausea and vomiting. It is a phosphorylated pro-drug preparation (injection) of netupitant, the active component. The prevention of chemotherapy-induced nausea and vomiting is considered important in clinical practice. Taiho acquired exclusive development and marketing rights for fosnetupitant in Japan under a license agreement signed in April 2011 with Helsinn Healthcare SA and has conducted clinical trials in Japan since then. The new drug application is based on the results of a Phase III clinical trial comparing the efficacy and safety of fosnetupitant and fosaprepitant (NK1 receptor antagonist) in patients receiving highly emetogenic chemotherapy. In the trial, either fosnetupitant (235 mg) or fosaprepitant (150 mg) was administered in a single I.V. dose prior to administration of the chemotherapeutic agent, in combination with palonosetron (5-HT3 receptor antagonist) and dexamethasone. Currently, the drug is in Registration stage of its development for the treatment of chemotherapy induced nausea and vomiting.

• APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. Currently the drug is in Phase II stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

• CAM2047: Camurus

CAM2047 is a long-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. Currently the drug is in Phase I stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

The Chemotherapy Induced Nausea and Vomiting Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment.
• Chemotherapy Induced Nausea and Vomiting Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market

Explore groundbreaking therapies and clinical trials in the Chemotherapy Induced Nausea and Vomiting Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Chemotherapy Induced Nausea and Vomiting Drugs

Chemotherapy Induced Nausea and Vomiting Companies

Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.

Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Chemotherapy Induced Nausea and Vomiting Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers

Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report

• Coverage- Global
• Chemotherapy Induced Nausea and Vomiting Companies- Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.
• Chemotherapy Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Palonosetron Hydrochloride Buccal Film 0.25 Mg, Akynzeo, Fosaprepitant Dimeglumine and others.
• Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chemotherapy Induced Nausea and Vomiting Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Chemotherapy Induced Nausea and Vomiting Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Chemotherapy Induced Nausea and Vomiting: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Chemotherapy Induced Nausea and Vomiting Collaboration Deals
9. Late Stage Products (Registration)
10. Fosnetupitant: Helsinn Healthcare SA
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. APD403: Acacia Pharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CAM2047: Camurus
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Chemotherapy Induced Nausea and Vomiting Key Companies
23. Chemotherapy Induced Nausea and Vomiting Key Products
24. Chemotherapy Induced Nausea and Vomiting- Unmet Needs
25. Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
26. Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
27. Chemotherapy Induced Nausea and Vomiting Analyst Views
28. Chemotherapy Induced Nausea and Vomiting Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight